Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | RAF1 | P04049 | 11/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701906 | 0.88 | EPHX2 (0.70) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701993 | 0.81 | EPHX2 (0.79) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701988 | 0.77 | EPHX2 (0.50) | EPHX2BRAFRAF1 | |
| SCHEMBL14508019 | 0.75 | EPHX2 (0.43) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701899 | 0.75 | EPHX2 (0.48) | EPHX2BRAFRAF1 | |
| SCHEMBL13701901 | 0.74 | EPHX2 (0.48) | EPHX2BRAFRAF1 | |
| SCHEMBL13702013 | 0.72 | EPHX2 (0.76) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13702022 | 0.71 | EPHX2 (0.70) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701878 | 0.71 | EPHX2 (0.74) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701989 | 0.70 | EPHX2 (0.75) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | EPHX2 2/4885ALOX5 60/4885TBXAS1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.